Amplification of immune responses against a DNA-delivered idiotypic lymphoma antigen by fusion to the B subunit of E. coli heat labile toxin

Vaccine

Volumn 27, Issue 32, 2009, Pages 4289-4296

  Chen, Caleb G ^a,b,c   Lu, Yen Ta ^a,b   Lin, Marie ^a   Savelyeva, Natalia ^d   Stevenson, Freda K ^d   Zhu, Delin ^e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e Amcellgene Co Ltd   (China)

Author keywords

B cell lymphoma; DNA vaccine; E. coli heat labile enterotoxin; GM1 receptor; Idiotype

Indexed keywords

DNA VACCINE; ESCHERICHIA COLI ENTEROTOXIN; GANGLIOSIDE GM1; HYBRID PROTEIN; IDIOTYPIC ANTIBODY; IDIOTYPIC LYMPHOMA ANTIGEN; IMMUNOGLOBULIN IDIOTYPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BETA CHAIN; BINDING COMPETITION; CANCER IMMUNIZATION; CONTROLLED STUDY; EMBRYO; ESCHERICHIA COLI; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BACTERIAL TOXINS; CANCER VACCINES; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; G(M1) GANGLIOSIDE; LYMPHOMA; MICE; MICE, INBRED BALB C; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; VACCINES, DNA;

EID: 67649464215     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.025     Document Type: Article

References (41)

1. Rice J., Ottensmeier C.H., and Stevenson F.K. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8 2 (2008) 108-120
2. King C.A., Spellerberg M.B., Zhu D., Rice J., Sahota S.S., Thompsett A.R., et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4 (1998) 1281-1286
3. Campbell M.J., Esserman L., Byars N.E., Allison A.C., and Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 145 3 (1990) 1029-1036
4. Biragyn A., and Kwak L.W. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. Immunol Rev 170 (1999) 115-126
5. Benvenuti F., Burrone O.R., and Efremov D.G. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene Ther 7 7 (2000) 605-611
6. Syrengelas A.D., Chen T.T., and Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2 9 (1996) 1038-1041
7. Gerloni M., Castiglioni P., and Zanetti M. The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice. J Immunol 175 10 (2005) 6551-6559
8. Rappuoli R., Pizza M., Douce G., and Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 20 11 (1999) 493-500
9. de Haan L., and Hirst T.R. Cholera toxin and related enterotoxins: a cell biological and immunological perspective. J Nat Toxins 9 3 (2000) 281-297
10. Holmgren J., Harandi A.M., and Czerkinsky C. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev Vaccines 2 2 (2003) 205-217
11. Takahashi I., Marinaro M., Kiyono H., Jackson R.J., Nakagawa I., Fujihashi K., et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 173 (1996) 627-635
12. Nashar T.O., Webb H.M., Eaglestone S., Williams N.A., and Hirst T.R. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc Natl Acad Sci USA 93 1 (1996) 226-230
13. Tochikubo K., Isaka M., Yasuda Y., Kozuka S., Matano K., Miura Y., et al. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine 16 (1998) 150-155
14. Verweij W.R., de Haan L., Holtrop M., Agsteribbe E., Brands R., van Scharrenburg G.J., et al. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 16 (1998) 2069-2076
15. Wu H.Y., and Russell M.W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine 16 2-3 (1998) 286-292
16. Millar D.G., Hirst T.R., and Snider D.P. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin. Infect Immun 69 5 (2001) 3476-3482
17. Richards C.M., Aman A.T., Hirst T.R., Hill T.J., and Williams N.A. Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant. J Virol 75 4 (2001) 1664-1671
18. McKenzie S.J., and Halsey J.F. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 133 4 (1984) 1818-1824
19. Czerkinsky C., Russell M.W., Lycke N., Lindblad M., and Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun 57 4 (1989) 1072-1077
20. Lipscombe M., Charles I.G., Roberts M., Dougan G., Tite J., and Fairweather N.F. Intranasal immunization using the B subunit of the Escherichia coli heat-labile toxin fused to an epitope of the Bordetella pertussis P.69 antigen. Mol Microbiol 5 6 (1991) 1385-1392
21. Jagusztyn-Krynicka E.K., Clark-Curtiss J.E., and Curtiss III R. Escherichia coli heat-labile toxin subunit B fusions with Streptococcus sobrinus antigens expressed by Salmonella typhimurium oral vaccine strains: importance of the linker for antigenicity and biological activities of the hybrid proteins. Infect Immun 61 3 (1993) 1004-1015
22. Toida N., Hajishengallis G., Wu H.Y., and Russell M.W. Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues. Infect Immun 65 3 (1997) 909-915
23. George-Chandy A., Eriksson K., Lebens M., Nordstrom I., Schon E., and Holmgren J. Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells. Infect Immun 69 9 (2001) 5716-5725
24. Eriksson K., Fredriksson M., Nordstrom I., and Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infect Immun 71 4 (2003) 1740-1747
25. Lebens M., Sun J.B., Sadeghi H., Backstrom M., Olsson I., Mielcarek N., et al. A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. Vaccine 21 (2003) 514-520
26. Slavin S., and Strober S. Spontaneous murine B-cell leukaemia. Nature 272 5654 (1978) 624-626
27. Svennerholm A.M., Wikstrom M., Lindblad M., and Holmgren J. Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay. J Clin Microbiol 24 4 (1986) 585-590
28. Cavanagh L.L., Saal R.J., Grimmett K.L., and Thomas R. Proliferation in monocyte-derived dendritic cell cultures is caused by progenitor cells capable of myeloid differentiation. Blood 92 5 (1998) 1598-1607
29. Buchan S., Gronevik E., Mathiesen I., King C.A., Stevenson F.K., and Rice J. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J Immunol 174 10 (2005) 6292-6298
30. Aihara H., and Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16 9 (1998) 867-870
31. George A.J., Tutt A.L., and Stevenson F.K. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol 138 2 (1987) 628-634
32. Rice J., King C.A., Spellerberg M.B., Fairweather N., and Stevenson F.K. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine 17 23-24 (1999) 3030-3038
33. Corr M., Lee D.J., Carson D.A., and Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 184 4 (1996) 1555-1560
34. Chastain M., Simon A.J., Soper K.A., Holder D.J., Montgomery D.L., Sagar S.L., et al. Antigen levels and antibody titers after DNA vaccination. J Pharm Sci 90 (2001) 474-484
35. Liu M.A., McClements W., Ulmer J.B., Shiver J., and Donnelly J. Immunization of non-human primates with DNA vaccines. Vaccine 15 8 (1997) 909-912
36. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178 (1998) 92-100
37. Nchinda G., Kuroiwa J., Oks M., Trumpfheller C., Park C.G., Huang Y., et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 118 (2008) 1427-1436
38. Fredriksen A.B., Sandlie I., and Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther 13 4 (2006) 776-785
39. Kohne C., Johnson A., Tom S., Peers D.H., Gehant R.L., Hotaling T.A., et al. Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator. J Cell Biochem 75 (1999) 446-461
40. Aman A.T., Fraser S., Merritt E.A., Rodigherio C., Kenny M., Ahn M., et al. A mutant cholera toxin B subunit that binds GM1-ganglioside but lacks immunomodulatory or toxic activity. Proc Natl Acad Sci USA 98 (2001) 8536-8541
41. Fraser S.A., de Haan L., Hearn A.R., Bone H.K., Salmond R.J., Rivett A.J., et al. Mutant Escherichia coli heat-labile toxin B subunit that separates toxoid-mediated signaling and immunomodulatory action from trafficking and delivery functions. Infect Immun 71 (2003) 1527-1537